President and CEO Bengt Baron comments on the results for

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jul 18, 2014 at 2:15 AM

President and CEO Bengt Baron comments on the results for the second quarter of 2014

Increased sales and improved operating profit. Cloetta has continued to grow and showed growth for the fourth consecutive quarter. At the same time, both operating profit (EBIT) and underlying operating profit improved. This improvement took place despite the fact that EBIT for the quarter was impacted by negative currency effects. The changes in exchange rates that arose during the first quarter will be offset through price increases that were implemented as of 1 July 2014. Operating profit improved significantly to SEK 85m (54), mainly because our restructuring costs are coming to an end, entirely according to plan. As a result, our underlying EBIT is increasingly converging with the operating profit. Underlying EBIT improved somewhat, despite the negative currency impact, to SEK 110m (109). The underlying EBIT margin for the quarter was 9.4 per cent (9.6). Profit after tax increased to SEK 9m (–44). Cash flow from operating activities strengthened to SEK 44m (–23). The confectionery market The market for confectionery has predominantly been flat to slightly negative in our markets, except Sweden where the market was positive. In Finland the market continued to be weak and in the Netherlands the market declined after a positive first quarter. The Italian market continued to decline during the second quarter. Thus, the Italian market continues to be unstable. Cloetta showing continued growth Our efforts to drive growth, both organic and through acquisitions, are delivering results. For the fourth consecutive quarter, we achieved organic growth in spite of the negative sales development in Italy and reduced sales of contract manufacturing. In addition, the acquisitions of Nutisal and The Jelly Bean Factory are contributing further to our growth momentum. In total, sales were up by 9.5 per cent during the quarter, of which 2.2 per cent was organic growth and 3.7 per cent consisted of currency effects. Sales increased in all markets, aside from Italy. Sales growth was strong in most markets, driven by both new product launches and a sustained focus on existing products. Furthermore, Cloetta’s market shares grew in the majority of markets. Sales of nuts under the Nutisal brand showed positive development, but a continued sharp decrease in contract manufacturing compared to last year meant that total sales of nuts were down. We will continue to focus on driving branded sales over contract manufacturing. Restructuring programme nearly completed The factories that have taken over production from the closed factory in Gävle are now producing the same volume as the Gävle factory before its closure. This milestone means that the factory restructuring process, that was initiated in 2012, can be considered essentially completed. Production of the chocolate product Tupla in Ljungsbro has started and production is expected to be fully insourced during the third quarter. Acquisition of The Jelly Bean Factory contributes to profitable growth In May, Cloetta acquired the Irish company Aran Candy Ltd. and its brand The Jelly Bean Factory. The acquisition is yet another step in the strategy to expand our offering within Munchy Moments. This will significantly strengthen Cloetta’s position in the UK and the premium brand can be rolled out in our current core markets over time. The Jelly Bean Factory will contribute to continued profitable growth for Cloetta. Growth focus paying off We are executing in line with the laid out strategy. The factory restructurings are virtually completed, organic sales are growing, and we have been able to make complementary acquisitions to further boost the growth rate. The new pick -and-mix concept that we will start to deliver to Coop Sweden in 2015 will also contribute to accelerating growth. In terms of profitability, we have taken a step in the right direction during the quarter. Looking ahead, we will continue to focus on profitable growth and integration of the acquisitions we have made, while at the same time ensuring that the final synergies from the factory restructurings are realised. The information contained in this press release is such that Cloetta is required to disclose pursuant to the Swedish Financial Instruments Trading Act and/or the Swedish Securities Markets Act. The information was submitted for publication on 18 July 2014 at 08:00 a.m. CET. Media contact Jacob Broberg, SVP Corporate Communications & Investor Relations, 46 70 190 00 33. About Cloetta Cloetta, founded in 1862, is a leading confectionary company in the Nordic region, the Netherlands, and Italy. In total, Cloetta products are sold in more than 50 countries worldwide. Cloetta owns some of the strongest brands on the market, such as Läkerol, Cloetta, Jenkki, Kexchoklad, Malaco, Sportlife, Saila, Red Band and Sperlari. Cloetta has 11 production units in six countries. Cloetta’s class B-shares are traded on NASDAQ OMX Stockholm. More information about Cloetta is available on www.cloetta.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Princess Cruises Launches New Era at Celebration Key

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...